In 2018, it is estimated that approximately 18 million people worldwide were diagnosed and about 9.5 million people died from cancer.2
By 2025, new cancer cases worldwide are predicted to exceed 20 million annually.3
In the 1950s, researchers proposed that the immune system patrols the body to detect and destroy tumor cells. Scientists and researchers had previously focused on cancer cells and treating cancer as a genetic disease.4
Now the focus is shifting to the microenvironment in which cancer grows, including the immune system – an approach called immuno-oncology.4
Immuno-Oncology has the potential to transform how physicians treat cancer and how patients benefit.4
We believe in the work we do and are working with the entire cancer community to help people with cancer and their caregivers better navigate their journeys.
Ultimately, our progress in changing the outcomes of cancer would not be possible without:
... the participation of patients in clinical trials
... the support and involvement of the physicians who believe in the importance of advancing the care for patients through innovative clinical trials
... the patient advocacy community who helps support people with cancer through their journeys
1 American Cancer Society
2 Bray et all, Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, Cancer Journal for Clinicians, August 2018;68:394–424,
3 World Cancer Report 2014, IARC
4 merck.com > Oncology